Published August 10, 2026
A $24 Billion Industry Where Three-Quarters of Operators Can’t Turn a Profit
Here is one of the strangest facts in American business. The legal cannabis industry generates nearly $24 billion in annual sales. Demand is enormous and growing. Products fly off shelves. And yet, by the most-cited industry measure, only about 24.4% of U.S. cannabis operators are profitable on an after-tax basis.
Sit with the contrast. Roughly 65% of all U.S. small businesses turn a profit. In cannabis — a product people line up to buy, in a market expanding every year — it’s barely one in four. Whitney Economics, the firm behind that figure, found it had dropped 42% from the year before. Beau Whitney, the economist behind the survey, put it bluntly: about a third of operators are actively losing money, most of the rest are just breaking even, and “that’s not a sustainable marketplace.”
So what’s going wrong? The instinctive answer is “it must be a bad business” — oversupply, mismanagement, a fad cooling off. That answer is wrong, and understanding why it’s wrong is the single most important thing to grasp about the economics of legal weed. These companies are, for the most part, running perfectly good businesses. They’re being strangled by a tax rule written for drug dealers in 1982.
The Paradox: Great Gross Margins, Catastrophic Net Margins
Here’s the number that cracks the mystery open. Cannabis companies have healthy gross profit margins — the money left after the direct cost of producing what they sell. Industry gross margins typically run 45% to 55%, and climb to 52% to 60% in limited-license states. Those aren’t distressed-business numbers. Those are the margins of a genuinely strong consumer-products company. A grocery store dreams of margins like that.
You can see it in the public companies’ own SEC filings. In early 2026, TerrAscend reported a 52.8% gross margin; Jushi reported 45%, expanded 460 basis points year-over-year. On the fundamental operation — grow product, sell product — these businesses work.
Now here’s what happens on the way to the bottom line. After that same tax rule takes its cut, industry net margins collapse to somewhere between 5% and 12% — and for many operators, below zero. A business that keeps 50 cents of gross profit on the dollar ends up keeping a nickel, or nothing. The productive engine is fine. Something is siphoning off nearly everything it produces before it reaches the owner. That something has a name: Section 280E.
Section 280E: The Rule That Taxes Cannabis Into the Ground
Section 280E of the Internal Revenue Code is short, old, and devastating. Passed in 1982 after a convicted cocaine trafficker successfully deducted business expenses on his taxes, it says that any business “trafficking” in a Schedule I or II controlled substance cannot deduct ordinary business expenses from its federal taxes.
For a normal business, that would be unthinkable — you’re taxed on profit, which is revenue minus expenses. 280E says a cannabis business can only subtract its cost of goods sold, and then gets taxed on everything above that as if it were profit. Rent, payroll, marketing, utilities, security, insurance, professional fees — the entire cost of actually operating — become non-deductible. The business pays federal tax on money it never got to keep.
The result is effective tax rates that routinely hit 50% or higher — some operators pay north of 52.5% — several times what a comparable non-cannabis business pays. Whitney Economics estimated the industry paid an extra $2.3 billion in excess taxes in a single year purely because of Schedule I status, a figure projected to climb toward $5.2 billion by 2030 if nothing changes. As Whitney put it, “operators cannot make money, regardless of how much money they actually generate.” That’s not a metaphor. It’s arithmetic. You can run a flawless dispensary and still hand so much to the IRS that you finish the year underwater.
This is why the profitability crisis isn’t a business-quality story. It’s a tax story. The same company, selling the same products at the same volume, would be comfortably profitable if it were allowed the deductions every other business takes for granted.
The Other Pressures Are Real — but 280E Is the Multiplier
To be fair and complete, 280E isn’t the only thing squeezing operators, and honesty requires naming the rest.
Price compression is brutal. As markets mature and oversupply builds, wholesale and retail prices fall. Retail gross margins have compressed from 52.6% in 2021 to 42.7% in 2025 — still healthy, but shrinking. Overproduction in many states has flooded the market. Hemp-derived THC products, sold with lighter regulation and no 280E burden, have siphoned off customers. Capital is scarce and expensive — federally illegal businesses can’t access normal banking or cheap loans, so debt service eats cash. More than 4,000 cannabis businesses surrendered their licenses over an 18-month stretch; 23 states saw regulated sales decline in 2025.
But notice how 280E interacts with all of it. Every one of those pressures is survivable in a normal tax environment. Thin margins are manageable when you can deduct expenses; they’re fatal when you can’t. 280E doesn’t act alone — it takes every other challenge in the industry and multiplies it, turning “difficult” into “impossible.” It’s the reason a price dip that a normal retailer would absorb pushes a dispensary into the red. It’s the amplifier under every other problem.
Why This Might Be About to Change
Here’s the development that makes this the right moment to understand all of this — because the central constraint may be loosening for the first time.
In April 2026, the federal government partially rescheduled cannabis, immediately moving FDA-approved and state-licensed medical cannabis to Schedule III. And 280E, by its own terms, applies only to Schedule I and II substances. So the moment qualifying medical cannabis left Schedule I, it stepped outside 280E’s reach — creating, for the first time, a 280E relief pathway for qualifying operators.
The estimated impact is enormous. According to Headset, a typical qualifying dispensary would save around $268,000 annually. Industry-wide, the relief is estimated at $1.6 to $2.2 billion per year. For a sector where net margins hover in the single digits, dropping the effective tax rate from 50%+ toward normal is potentially the difference between that 24% profitability figure and something that looks like a real industry. Some operators are already filing amended returns and taking aggressive positions that they’re no longer subject to 280E — one company has openly argued the IRS can’t dispute that medical cannabis falls outside Schedule I “without contradicting the president, the acting attorney general and HHS.”
The honest caveats: this relief currently applies to qualifying medical operators, not the whole industry; the broader rescheduling that would free everyone is still grinding through its process; and the IRS has not fully clarified how it will treat these positions, so operators taking them are accepting real risk. But directionally, the single biggest reason cannabis can’t make money is, for the first time, cracking.
What This Means for Operators and Investors
A few practical takeaways from all this.
Judge cannabis businesses on gross margin and operations, not just net profit — for now. A company posting thin or negative net margins under 280E may be operationally excellent and poised to become highly profitable the moment the tax burden lifts. The bottom line is currently measuring the tax regime as much as the business. Gross margin and cash flow from operations tell you more about the underlying company than net income does.
280E status is now a live variable in valuation. Whether and how fast an operator can exit 280E — via the medical-rescheduling pathway or eventual full rescheduling — may matter more to its future profitability than anything happening on the sales floor. That’s an unusual situation: the most important number on the horizon is a tax classification, not a market metric.
Survival to the other side is the game. The brutal logic of the moment is that operators who can stay solvent long enough to reach 280E relief stand to see their economics transform. The ones who run out of capital first won’t be around to enjoy it. That’s why disciplined balance sheets, lean operations, and access to capital matter so much right now — not because they win the current game, but because they’re how you survive until the rules change.
The Bottom Line
The cannabis profitability crisis is real — only about a quarter of operators make money, a third are losing it, and thousands have handed back their licenses. But the crisis is badly misunderstood. This is not an industry that fails at business. On the numbers that measure actual operations — gross margin, demand, sales — it works fine, sometimes beautifully. It fails at one specific thing: a 1982 tax rule that forces it to pay taxes on money it never keeps.
That distinction matters enormously, because business-quality problems are hard to fix and tax-rule problems can vanish with a change in classification. Cannabis spent years being told it couldn’t make money. The truer statement is that it was never allowed to. And in April 2026, for the first time, the door cracked open.
Whether the industry walks through it depends on how fast rescheduling moves — and on how many operators can stay alive long enough to find out.
The business-side companion to our coverage of the industry’s asset-light pivot and first-ever sales decline — see those for the full picture. Follow the rest at our Cannabis Business hub.
Sources:
MJBizDaily / Whitney Economics (the 24.4% profitability figure, the 42% year-over-year drop, methodology): https://mjbizdaily.com/less-than-25-of-u-s-cannabis-operators-profitable-study-finds/
Forbes / Whitney Economics (the 52.5% effective tax rate, $2.3B→$5.2B excess-tax projection, “operators cannot make money” quote): https://www.forbes.com/sites/benjaminadams/2024/07/26/only-27-of-us-cannabis-businesses-are-profitable-survey-shows/
Cova Software (the 45–55% gross / 5–12% net margin figures, retail margin compression 52.6%→42.7%, the April 2026 relief pathway + Headset savings estimates): https://www.covasoftware.com/blog/cannabis-industry-statistics-2026-data-trends-market-analysis
TerrAscend SEC Form 8-K (primary source — 52.8% gross margin): https://www.sec.gov/Archives/edgar/data/0001778129/000119312526179245/tsndf-ex99_1.htm
Jushi Holdings SEC Form 8-K (primary source — 45% gross margin, 460bps expansion): https://www.sec.gov/Archives/edgar/data/0001909747/000117184326003304/exh_991.htm
Cannabis Industry Lawyer (280E mechanics, “fewer than 25% profitable… $24B in sales,” the existential-constraint framing): https://www.cannabisindustrylawyer.com/how-much-does-a-dispensary-make/